PURPOSE: The tumor suppressor gene p53 plays a crucial role in cell cycle control and apoptosis in response to DNA damages. p53 gene mutations and allelic losses at 17p are one of the most common genetic alterations in primary head and neck squamous cell carcinoma (HNSCC). Alterations of the p53 gene have been shown to contribute to carcinogenesis and drug resistance. PATIENTS AND METHODS: In this prospective series, patients with HNSCC were treated with cisplatin-fluorouracil neoadjuvant chemotherapy. p53 status was characterized in 106 patients with HNSCC (p53 mutations, allelic losses at p53 locus, and plasma anti-p53 antibodies) to determine the existence of a relationship between p53 gene status and response to neoadjuvant chemotherapy. RESULTS: Exons 4 to 9 of the p53 gene were analyzed, and mutations were found in 72 of 106 patients with HNSCC. p53 mutations were associated with loss of heterozygosity at chromosome 17p (P <.001). The prevalence of p53-mutated tumors was higher in the group of patients with nonresponse to neoadjuvant chemotherapy than in the group of responders (81% v 61%, respectively; P <.04). When compiling p53 mutations and anti-p53 antibodies in plasma, the correlation between p53 status and response to chemotherapy was significant (87% v 57%, respectively; P =.003). A multivariate analysis showed that p53 status is an independent predictive factor of response to chemotherapy. CONCLUSION: This prospective study suggests that p53 status may be a useful indicator of response to neoadjuvant chemotherapy in HNSCC.
PURPOSE: The tumor suppressor gene p53 plays a crucial role in cell cycle control and apoptosis in response to DNA damages. p53 gene mutations and allelic losses at 17p are one of the most common genetic alterations in primary head and neck squamous cell carcinoma (HNSCC). Alterations of the p53 gene have been shown to contribute to carcinogenesis and drug resistance. PATIENTS AND METHODS: In this prospective series, patients with HNSCC were treated with cisplatin-fluorouracil neoadjuvant chemotherapy. p53 status was characterized in 106 patients with HNSCC (p53 mutations, allelic losses at p53 locus, and plasma anti-p53 antibodies) to determine the existence of a relationship between p53 gene status and response to neoadjuvant chemotherapy. RESULTS: Exons 4 to 9 of the p53 gene were analyzed, and mutations were found in 72 of 106 patients with HNSCC. p53 mutations were associated with loss of heterozygosity at chromosome 17p (P <.001). The prevalence of p53-mutated tumors was higher in the group of patients with nonresponse to neoadjuvant chemotherapy than in the group of responders (81% v 61%, respectively; P <.04). When compiling p53 mutations and anti-p53 antibodies in plasma, the correlation between p53 status and response to chemotherapy was significant (87% v 57%, respectively; P =.003). A multivariate analysis showed that p53 status is an independent predictive factor of response to chemotherapy. CONCLUSION: This prospective study suggests that p53 status may be a useful indicator of response to neoadjuvant chemotherapy in HNSCC.
Authors: Yin Wu; Marshall R Posner; Lisa M Schumaker; Nikolaos Nikitakis; Olga Goloubeva; Ming Tan; Changwan Lu; Sana Iqbal; Jochen Lorch; Nicholas J Sarlis; Robert I Haddad; Kevin J Cullen Journal: Cancer Date: 2011-08-25 Impact factor: 6.860
Authors: Silvia S Borkosky; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Esra Gunduz; Mahmoud A L Sheikh Ali; Andrea P Rodriguez; Mehmet Zeynel Cilek; Susumu Tominaga; Noboru Yamanaka; Kenji Shimizu; Noriyuki Nagai Journal: J Cancer Res Clin Oncol Date: 2008-11-08 Impact factor: 4.553
Authors: Orsolya Rusz; Margit Pál; Éva Szilágyi; László Rovó; Zoltán Varga; Bernadett Tomisa; Gabriella Fábián; Levente Kovács; Olga Nagy; Petra Mózes; Zita Reisz; László Tiszlavicz; Péter Deák; Zsuzsanna Kahán Journal: Pathol Oncol Res Date: 2016-07-13 Impact factor: 3.201
Authors: Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova Journal: Pathol Oncol Res Date: 2014-08-23 Impact factor: 3.201
Authors: A B P van Kuilenburg; M-C Etienne-Grimaldi; A Mahamat; J Meijer; P Laurent-Puig; S Olschwang; M-P Gaub; R C M Hennekam; D Benchimol; S Houry; C Letoublon; F-N Gilly; D Pezet; T Andre; J-L Faucheron; A Abderrahim-Ferkoune; R Vijzelaar; B Pradere; G Milano Journal: Pharmacogenomics J Date: 2014-10-28 Impact factor: 3.550
Authors: P Alhopuro; S K Ylisaukko-Oja; W J Koskinen; P Bono; J Arola; H J Järvinen; J-P Mecklin; T Atula; R Kontio; A A Mäkitie; S Suominen; I Leivo; P Vahteristo; L-M Aaltonen; L A Aaltonen Journal: J Med Genet Date: 2005-09 Impact factor: 6.318